Sleep Disorders

Stay informed on the latest therapeutic advancements with this clinical recap from the NeurologyLive® team, featuring a centralized look at 7 FDA-approved treatments from the first quarter of 2026.

Alkermes has initiated the phase 3 Brilliance program for alixorexton in narcolepsy, building on prior phase 1 and 2 data showing significant improvements in wakefulness and daytime sleepiness.

Catch up on any of the neurology headlines you may have missed in March 2026, compiled into 1 place by the NeurologyLive® team.

A cross-sectional study suggests excessive daytime sleepiness may represent an independent, nonmotor feature of idiopathic normal pressure hydrocephalus, separate from apnea or disease severity.

A new obstructive sleep apnea study suggested that fatigue and objective daytime sleepiness are uncorrelated, challenging the use of the Epworth Sleepiness Scale as a measure of sleepiness.

In a preclinical study, subthalamic nucleus (STN) low-beta power negatively correlated with wake quantity, whereas STN and motor cortex high-beta power demonstrated a positive correlation with wakefulness.

Sleep medicine specialist Karin Johnson, MD, FAAN, FAASM, shared the main takeaways from a recently published guideline on evaluating and managing obstructive sleep apnea in hospitalized adults.

From FDA regulatory milestones for investigational agents to emerging clinical data across sleep disorders, this roundup highlights notable developments shaping the evolving landscape of orexin-targeted therapies.

New findings from a phase 3 trial conducted in China showed that solriamfetol boosted wakefulness and reduced daytime sleepiness in patients with obstructive sleep apnea, with manageable adverse effects.

A post hoc analysis of the AMPA observational study found that adjunctive perampanel did not worsen daytime sleepiness over 12 months in patients with focal epilepsy while maintaining substantial seizure reduction.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

Catch up on any of the neurology headlines you may have missed in February 2026, compiled into 1 place by the NeurologyLive® team.

A cross-sectional analysis of nearly 28,000 middle-aged adults found that excessive daytime sleepiness is strongly associated with both sleep characteristics and modifiable psychological factors, highlighting the need for integrated prevention strategies.

A new study showed that higher baseline Epworth Sleepiness Scale scores were associated with greater early continuous positive airway pressure adherence in patients with obstructive sleep apnea.

In honor of Black History Month, neurologist Na Tosha Gatson, MD, PhD, reflects on structural inequities in neuro-oncology and advancing equity through mentorship, trial design, and institutional policy.

In early-morning shift workers with shift work disorder, solriamfetol significantly improved objective and subjective measures of sleepiness compared with placebo in a trial published in the New England Journal of Medicine.

Bruce Ovbiagele, MD, MSc, MAS, MBA, founding president of the Society for Equity Neuroscience (SEQUINS) reflects on Black History Month, SEQUINS initiatives, and the policy and guideline reforms needed to advance brain health equity in 2026 and beyond.

New data suggest that prophylactic treatment with anti-calcitonin gene-related peptide monoclonal antibodies may be associated with improvements in sleep quality and daytime sleepiness among patients with migraine.

The FDA expands pitolisant, marketed as Wakix, to treat cataplexy in pediatric patients 6 years and older with narcolepsy, making pitolisant the only nonscheduled option for excessive daytime sleepiness and cataplexy attacks.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending February 14, 2026. [WATCH TIME: 4 minutes]

Catch up on any of the neurology headlines you may have missed in January 2026, compiled into 1 place by the NeurologyLive® team.

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

ACP urged to drop “provider” for physicians, warning it blurs expertise, commodifies care, and erodes professional identity, trust, and the patient relationship.